Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb;18(2):e13255.
doi: 10.1111/irv.13255.

Vaccine effectiveness against influenza hospitalisation in adults during the 2022/2023 mixed season of influenza A(H1N1)pdm09, A(H3N2) and B circulation, Europe: VEBIS SARI VE hospital network

Angela M C Rose  1 , Francisco Pozo  2   3 , Iván Martínez-Baz  3   4 , Clara Mazagatos  3   5 , Nathalie Bossuyt  6 , John Paul Cauchi  7 , Goranka Petrović  8 , Isabela I Loghin  9 , Roberta Vaikutyte  10 , Silke Buda  11 , Ausenda Machado  12 , Róisín Duffy  13 , Beatrix Oroszi  14 , Jennifer Howard  1 , Aitziber Echeverria  3   4 , Cristina Andreu  15 , Cyril Barbezange  6 , Aušra Džiugytė  7 , Diana Nonković  16 , Corneliu-Petru Popescu  17 , Fausta Majauskaite  18 , Kristin Tolksdorf  11 , Verónica Gomez  12 , Lisa Domegan  13 , Judit Krisztina Horváth  14 , Jesús Castilla  3   4 , Miriam García  19 , Thomas Demuyser  20 , Maria-Louise Borg  7 , Irena Tabain  8 , Mihaela Lazar  21 , Ieva Kubiliute  18 , Ralf Dürrwald  11 , Raquel Guiomar  12 , Joan O'Donnell  13 , Katalin Kristóf  14 , Nathalie Nicolay  22 , Sabrina Bacci  22 , Esther Kissling  1 ; VEBIS SARI VE network team; Belgium SARI Surveillance Network (BelsariNet)
Collaborators, Affiliations

Vaccine effectiveness against influenza hospitalisation in adults during the 2022/2023 mixed season of influenza A(H1N1)pdm09, A(H3N2) and B circulation, Europe: VEBIS SARI VE hospital network

Angela M C Rose et al. Influenza Other Respir Viruses. 2024 Feb.

Abstract

We conducted a multicentre hospital-based test-negative case-control study to measure vaccine effectiveness (VE) against PCR-confirmed influenza in adult patients with severe acute respiratory infection (SARI) during the 2022/2023 influenza season in Europe. Among 5547 SARI patients ≥18 years, 2963 (53%) were vaccinated against influenza. Overall VE against influenza A(H1N1)pdm09 was 11% (95% CI: -23-36); 20% (95% CI: -4-39) against A(H3N2) and 56% (95% CI: 22-75) against B. During the 2022/2023 season, while VE against hospitalisation with influenza B was >55%, it was ≤20% for influenza A subtypes. While influenza vaccination should be a priority for future seasons, improved vaccines against influenza are needed.

Keywords: SARI patients; hospital; influenza; test-negative design; vaccine effectiveness.

PubMed Disclaimer

Conflict of interest statement

No conflict of interest declared.

Figures

FIGURE 1
FIGURE 1
Countries and study sites participating in the Vaccine Effectiveness, Burden and Impact Studies (VEBIS) hospital network by provision of data for this analysis, Europe, 2022–2023 influenza season. Participating sites: Belgium (BE), Croatia (HR), Czechia (CZ), France (FR), Germany (DE), Hungary (HU), Ireland (IE), Lithuania (LT), Malta (MT), Portugal (PT), Romania (RO), Spain (11 regions: ES; Navarra region: NA). Included in this analysis: BE, ES, DE, HR, LT, MT, NA, PT, RO.
FIGURE 2
FIGURE 2
Number of severe acute respiratory infection (SARI) patients by case status and week of vaccination or swab, Vaccine Effectiveness, Burden and Impact Studies (VEBIS) in the hospital setting, influenza 2022/2023 season, Europe (N = 5547).
See this image and copyright information in PMC

References

    1. World Health Organization (WHO) . Recommended composition of influenza virus vaccines for use in the 2022‐2023 northern hemisphere influenza season [Internet]. 2022. Available at: https://cdn.who.int/media/docs/default-source/influenza/who-influenza-re...
    1. World Health Organisation and European Centre for Disease Prevention and Control . Flu News Europe season overview. 2023. Available at: https://flunewseurope.org/SeasonOverview
    1. Kissling E, Maurel M, Emborg HD, et al. Interim 2022/23 influenza vaccine effectiveness: six European studies, October 2022 to January 2023. Eurosurveillance. 2023;28(21):2300116. doi:10.2807/1560-7917.ES.2023.28.21.2300116 - DOI - PMC - PubMed
    1. I‐MOVE influenza and COVID‐19 networks . I‐MOVE‐COVID‐19 hospital network VE generic protocol [internet]. Paris, France: Epiconcept; 2021. Available at: https://www.imoveflu.org/wp-content/uploads/2021/03/08feb2021_draft_gene...
    1. European Centre for Disease Prevention and Control . Core protocol for ECDC VEBIS studies of COVID‐19 vaccine effectiveness against hospitalisation with severe acute respiratory infection laboratory‐confirmed with SARS‐CoV‐2 or seasonal influenza ‐ version 2.0 [Internet]. Stockholm: ECDC; 2023. Available at: https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-vaccin...

Publication types

Substances